A detailed history of Bank Of Montreal transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 524,931 shares of HALO stock, worth $31.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
524,931
Previous 519,430 1.06%
Holding current value
$31.3 Million
Previous $21.1 Million 30.08%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $207,992 - $288,252
5,501 Added 1.06%
524,931 $27.5 Million
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $501,427 - $624,551
14,888 Added 2.95%
519,430 $21.1 Million
Q4 2023

Feb 08, 2024

BUY
$33.32 - $42.1 $1.73 Million - $2.19 Million
51,943 Added 11.48%
504,542 $18.6 Million
Q3 2023

Nov 01, 2023

SELL
$36.46 - $44.03 $1.19 Million - $1.44 Million
-32,619 Reduced 6.72%
452,599 $17.3 Million
Q2 2023

Aug 02, 2023

BUY
$30.28 - $38.74 $5.12 Million - $6.56 Million
169,245 Added 53.56%
485,218 $17.5 Million
Q1 2023

Jun 13, 2024

SELL
$32.86 - $55.7 $1.55 Million - $2.62 Million
-47,085 Reduced 9.06%
472,345 $18 Million
Q4 2022

Feb 01, 2023

SELL
$40.06 - $59.44 $4.62 Million - $6.86 Million
-115,423 Reduced 26.76%
315,973 $18 Million
Q3 2022

Nov 10, 2022

BUY
$38.53 - $51.78 $15.8 Million - $21.3 Million
411,341 Added 2051.06%
431,396 $17.5 Million
Q2 2022

Aug 11, 2022

BUY
$37.35 - $48.3 $56,398 - $72,933
1,510 Added 8.14%
20,055 $941,000
Q1 2022

May 12, 2022

BUY
$31.97 - $41.06 $15,921 - $20,447
498 Added 2.76%
18,545 $746,000
Q4 2021

Feb 11, 2022

SELL
$31.82 - $40.75 $3.2 Million - $4.1 Million
-100,702 Reduced 84.8%
18,047 $736,000
Q3 2021

Nov 12, 2021

SELL
$38.47 - $46.42 $94,020 - $113,450
-2,444 Reduced 2.02%
118,749 $4.71 Million
Q2 2021

Aug 12, 2021

BUY
$38.84 - $51.31 $4.71 Million - $6.22 Million
121,193 New
121,193 $5.55 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.31B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.